New drug ANXV aims to save sight in diabetic and vein occlusion patients
NCT ID NCT07259928
First seen Jan 11, 2026 · Last updated May 19, 2026 · Updated 19 times
Summary
This early study tests a new drug, ANXV, in 12 adults with diabetic retinopathy or retinal vein occlusion. The main goal is to check if ANXV is safe and if it can improve vision or reduce the need for other treatments. Participants receive ANXV as a 30-minute infusion daily for 5 days and are followed for 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINAL VEIN OCCLUSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Retina Clinic London
RECRUITINGLondon, W1G9AX, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.